Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $162.78
    -5.01 (-2.99%)

    Market Cap: $10.73B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Repligen Corporation (RGEN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Repligen (RGEN) to earn $2.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $848.82M. Of 20 analysts, 16 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.05, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.

    RatingAnalystsShare
    Strong Buy315.0%
    Buy1365.0%
    Hold420.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 28.0% and revenue estimates rise 26.1%.

    Fiscal year ending Dec 31, 2026
    $2.07
    EPS consensus, revenue $848.82M
    Fiscal year ending Dec 31, 2027
    $2.65
    EPS consensus, revenue $1.07B
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.07$2.05 to $2.0920$848.82M$845.54M to $853.40M20
    Dec 31, 2027$2.65$2.47 to $2.9219$1.07B$1.05B to $1.10B19

    Quarterly Estimates

    The EPS consensus rises from $0.53 for the quarter ending Dec 31, 2026 to $0.60 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.53$0.49 to $0.5719$244.68M$215.01M to $257.99M20
    Mar 31, 2027$0.60$0.53 to $0.6710$250.28M$245.60M to $252.70M10

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 20 upward and 12 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202685
    Fiscal year ending Dec 31, 202784
    Quarter ending Mar 31, 202743

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 is where it was 90 days ago.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.07$2.07$2.06$2.07$2.07+0.4%
    Fiscal year ending Dec 31, 2027$2.65$2.65$2.63$2.63$2.64+0.6%
    Quarter ending Mar 31, 2027$0.60$0.59$0.59$0.59$0.59+0.9%

    Frequently Asked Questions About RGEN

    What is the RGEN stock forecast?

    Consensus analyst estimates put Repligen's EPS at $2.07 for the fiscal year ending Dec 31, 2026, on revenue of $848.82M. The consensus rating from 20 analysts is Buy.

    How do analysts rate RGEN stock?

    Of 20 analysts covering Repligen, 3 rate it Strong Buy, 13 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RGEN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.07, with estimates from $2.05 to $2.09 from 20 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.65, with estimates from $2.47 to $2.92 from 19 analysts.

    What revenue do analysts expect from Repligen next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $848.82M, with estimates from $845.54M to $853.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.07B, with estimates from $1.05B to $1.10B.

    How many analysts cover RGEN?

    20 analysts rate Repligen stock, and 20 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.